[go: up one dir, main page]

GB202106027D0 - Antibody - Google Patents

Antibody

Info

Publication number
GB202106027D0
GB202106027D0 GBGB2106027.2A GB202106027A GB202106027D0 GB 202106027 D0 GB202106027 D0 GB 202106027D0 GB 202106027 A GB202106027 A GB 202106027A GB 202106027 D0 GB202106027 D0 GB 202106027D0
Authority
GB
United Kingdom
Prior art keywords
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2106027.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncobiopharm Ltd
Original Assignee
Oncobiopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiopharm Ltd filed Critical Oncobiopharm Ltd
Priority to GBGB2106027.2A priority Critical patent/GB202106027D0/en
Publication of GB202106027D0 publication Critical patent/GB202106027D0/en
Ceased legal-status Critical Current

Links

GBGB2106027.2A 2021-04-28 2021-04-28 Antibody Ceased GB202106027D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2106027.2A GB202106027D0 (en) 2021-04-28 2021-04-28 Antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2106027.2A GB202106027D0 (en) 2021-04-28 2021-04-28 Antibody

Publications (1)

Publication Number Publication Date
GB202106027D0 true GB202106027D0 (en) 2021-06-09

Family

ID=76193598

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2106027.2A Ceased GB202106027D0 (en) 2021-04-28 2021-04-28 Antibody

Country Status (1)

Country Link
GB (1) GB202106027D0 (en)

Similar Documents

Publication Publication Date Title
PL3872091T3 (en) Antibodies against sars-cov-2
IL308741A (en) Anti-sirp-alpha antibodies
RS66234B1 (en) Anti-ccr8 antibodies
GB202105110D0 (en) Anti-CD73 antibodies
ZA202108836B (en) Anti-epha4 antibody
GB202111905D0 (en) Antibodies
IL300142A (en) ANTI-IL13Ralpha2 ANTIBODIES
GB202014851D0 (en) SARS-COV-2 antibodies
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
SG11201913540VA (en) Anti-Podoplanin Antibody
GB202309981D0 (en) Antibody
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202015115D0 (en) ZIP12 Antibody
GB201919062D0 (en) Antibody
GB202106027D0 (en) Antibody
GB202105933D0 (en) Anti-IL1rap antibody
GB202014969D0 (en) ZIP12 antibody
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) Il-38-specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
GB202107517D0 (en) Antibodies
GB202104128D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)